Description

With a higher concentration of EPA/DHA, supplies nutrients to the ocular surface.

Omega-3 Fatty Acids: It has been seen that they have anti-inflammatory properties and also, they help to modify tear lipid profile,
to improve tear production and quality and thus, dry eye symptoms in dogs (1, 2, 4, 5, 6, 8, 9, 10, 11, 14).

Minerals (Zn, Cu): Antioxidant effect that helps improving dry eye syndrome symptoms and tear stability in dogs (1, 3, 7).

Lactoferrin: In humans has been proved an anti-inflammatory, antibacterial, antiviral and antifungal properties on the ocular surface (13, 15, 16).

Vitamins (C, E): Help to improve tear production and inflammation in the ocular surface in dogs (1, 3, 12).

COMPOSITION

Composition per Tablet (750mg): Omega-3 Fatty Acids (DHA + EPA, 60mg) (450mg), Lactoferrin (5mg), Magnesium stearate (10mg).

Composition per ML (1ml): Linseed oil (source of α-linolenic acid (ALA) (679mg), Fish oil (DHA + EPA, 87mg) (291mg) Lactoferrin (5mg).

Additives per Tablet /ML (750mg/1ml): Vitamins: Vitamin C, Vitamin E. Trace elements: Zinc (zinc sulfate) (2,5mgr),

Copper (Copper (II) sulphate, pentahydrate) (0,1mgr).

INSTRUCTIONS FOR USE

Oral administration, once daily, with one of the main meals.
From 0 to 5 kg: 1/2 tablet / 0.5ml
From 5 to 10 kg:1 tablet / 1ml
From 10 to 20 kg: 1. 1/2 tablets / 1.5ml

From 20 to 40 kg: 2 tablets / 2ml

Over 40kg: 3 tablets / 3ml

PRESENTATION

Solid presentation: 30 tablets

Liquid presentation: 75ml

STORAGE CONDITIONS
Store in a cool and dry place, protected from light.

REFERENCES

1. Destefanis S. et al (2016). Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment
in dogs affected by Keratoconjunctivitis sicca. BMC Veterinary Research 12:214. http://doi.org/10.1186/
s12917-016-0841-2.
2. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of
omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients.Brignole-Baudouin F1,
Baudouin C, Aragona P, Rolando M, Labetoulle M, Pisella PJ, Barabino S, Siou-Mermet R, Creuzot-Garcher C.
PubMed.gov. Acta Ophthalmol. 2011 Nov;89(7):e591-7
3. Jehn-Yu Huang Po-Ting Yeh Yu-Chih Hou (2016). A randomized, double-blind, placebo-controlled study of oral
antioxidant supplement therapy in patients with dry eye syndrome. Clinical Ophthalmology 2016:10 813–820. https://
doi.org/10.2147/OPTH.S106455.
4. Rand AL, Asbell PA. (2011). Current opinion in ophthalmology nutrition supplements for dry eye syndrome. Curr Opin
Ophthalmol. 22(4): 279–282. http:/doi.org/10.1097/ICU.0b013e3283477d23.
5. Mitchell A Jackson et al. (2011). Efficacy of a new prescription-only medical food supplement in alleviating signs
and symptoms of dry eye, with or without concomitant cyclosporine A. Clinical Ophthalmology 5:1201-6. http://
doi.org/10.2147/OPTH.S22647.
6. Oral flaxseed oil (Linum usitatissimum) in the treatment for dry-eye Sjögren’s syndrome patients].Pinheiro MN Jr1, dos
Santos PM, dos Santos RC, Barros Jde N, Passos LF, Cardoso Neto J. PubMed.gov. Arq Bras Oftalmol. 2007 Jul-
Aug;70(4):649-55. PMID:17906762
7. Zinc in the eye. Karcioglu AZ. Surv Ophthalmol 1982; 27:114–122.
8. Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multipledosing
trial comparing 2 sources of n-3 fatty acid. Barceló-Coblijn G1, Murphy EJ, Othman R, Moghadasian MH,
Kashour T, Friel JK. PubMed.gov Am J Clin Nutr. 2008 Sep;88(3):801-9.

9. Boerner C. Dry eye successfully treated with oral flaxseed oil. Ocular Surgery News, 15 de octubre de 2000, p147-148.
10. The Role of Omega-3 Dietary Supplementation in Blepharitis and Meibomian Gland Dysfunction (An AOS Thesis). Marian
S. Macsai, MD. Trans Am Oftalmol Soc Dec 2008; 106: 336-356.
11. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye.
Wojtowicz JC1, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP. PubMed. Cornea. 2011 Mar;30(3):308-14.
12. A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye
syndrome. Jehn-Yu Huang, Po-Ting Yeh, and Yu-Chih Hou. Clin Ophthalmol. 2016; 10: 813–820.
13. Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions. Jagat R.
Kanwar, Kislay Roy, Yogesh Patel, Shu-Feng Zhou, Manju Rawat Singh, Deependra Singh, Muhammad Nasir, Rakesh Sehgal,
Alka Sehgal, Ram Sarup Singh, Sanjay Garg and Rupinder K. Kanwar. Molecules 2015, 20, 9703-9731.
14. Alves D., Alborgetti G., Giuffrida R., Rógério M., Rodrigues D., Vasconcelos I., Franco F., Rangel H., Franco S. (2018). Oral
omega 3 in different proportions of EPA. DHA and antioxidants as adjuvant in treatment of Ketaroconjunctivitis Sicca in
dogs. Arquivos Brasileiros de Oftalmologia;81(5):421-428. http://doi.org/ 10.5935/0004-2749.20180081.
15. Vagge A. et al. (2020). Therapeutic Effects of Lactoferrin in Ocular Diseases: From Dry Eye Disease to Infections.
International Journal of Molecular Sciences, , 21, 6668; http://doi.org/10.3390/ijms21186668.
16. Kawashima M. et al. (2012). Dietary Lactoferrin Alleviates Age-Related Lacrimal Gland Dysfunction in Mice. PLoS ONE
7(3): e33148. http://doi.org/10.1371/journal.pone.0033148